Skip to main content
Equibles
CPIX logo

CPIX · Cumberland Pharmaceuticals Inc

Track CPIX — free

Use CPIX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$6.79 +0.04 (+0.59%) At close · Sep 4
Rebalance outlook locked
Market Cap
$101.74M
Shares
14.98M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.79 Open$6.75 Day$6.65–6.90 52W close$1.90–8.97 Avg vol 30d94K Short int326K · 2.2% float · 2.7d Short vol66% Last earningsAug 4, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 7

Up next

Next earnings call
Nov 3, 2026 Est · unconfirmed · in 8 wks
Latest filing: 10-Q
filed Aug 7, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$31.27M
Trailing 12 months
Net income (TTM)
−$10.92M
Trailing 12 months
Revenue growth YoY
-56.3%
Year over year
Operating margin
-30.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
22.1%
Trailing 12 months
Shares change YoY
+0.1%
Year over year · more shares
Price change (1Y)
+85.5%
Trailing year
Short interest
2.2%
Latest settlement · 2.7 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +41%
above
Price vs 50-day avg −6%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 69%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −13%
trailing
6-month return +122%
trailing
YTD return +71%
this year
Relative strength +107%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $7 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.18% of float · ▼ -15.6% MoM · 2.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
33 holders — mid 3-yr range
Squeeze score 51
elevated · 0–100
Fundamentals
Excellent
Revenue growth +17%
Y/Y
EPS growth +59%
Y/Y
Free cash flow $4.8M
Buyback $5.0M
authorized
Quant / Vol
risk profile
Very High
Volatility 88%
annualized · 1-yr
Max drawdown −48%
past year
ATR 9.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+41% Bullish
Price vs 50-day avg
−6% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
69% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $7 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.18% of float · ▼ -15.6% MoM · 2.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
33 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $7 · 69% Range high $9
vs 200-day avg +41% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CPIX
Cumberland Pharmaceuticals Inc
this stock
$101.74M +70.6% +16.7% — 2.2%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
 $66.37B — — — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $58.92B +18.3% — — 0.1%
GALDY
Galderma Group AG/ADR
 $45.51B -5.8% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $42.37B +16.5% +4.3% 59.6 3.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
33
% held
18.9%
Net QoQ
-85.1K sh
Top holder
Ikarian Capital, LLC
Held Float
View
Held by Funds
Fund positions
30
View
Short & Settlement
Short Interest Falling
Shares short
326.2K
Days to cover
2.7d
Change
-60.3K sh
View
Short Volume
Short vol %
66%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
1.7K
Value
$12.6K
As of
Aug 4, 2026
View
Off-Exchange
Off-exchange %
42.9%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$44.5M
Net income (FY)
$-2.8M
EPS diluted
$-0.19
View
Buybacks
Authorized
$5.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 28, 2026
This year
14
View
Earnings & Events
Earnings Calls
Last call
Aug 4, 2026
View

Performance

5D 20D 120D MTD YTD
CPIX -19.7% -13.0% +121.9% +1.5% +70.6%
SPY +0.1% -0.4% +15.1% +0.4% +12.9%
vs SPY -19.9% -12.6% +106.8% +1.1% +57.7%

Capital returns

Latest dividend
$1.50 / share · ex Aug 3, 2026
Paid (TTM)
$1.50 / share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Buyback program · as of Jul 13, 2026
Authorized
$5.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1087294 CUSIP 230770109 13F (30d) 26 filings 26 filers Visit website Investor relations